hcv ns3 protease

Sovaprevir is a non-structural 3 (NS3) protease inhibitor with antiviral activity for the treatment of HCV infection.

4-Phenoxybenzylamine inhibits the function of the NS3 protein by stabilizing an inactive conformation, with an IC50 of approximately 500 μM against HCV NS3 4a.

Vaniprevir is a non-covalent competitive HCV NS3 4A protease inhibitor, an antiviral drug that acts directly on the hepatitis C virus. Vaniprevir blocks the viral replication process by inhibiting the activity of HCV NS3 4A protease.

Faldaprevir is an orally effective, selective, non-covalent HCV NS3 4A protease inhibitor with high inhibitory activity against HCV 1a and 1b genotypes (Ki=2.6 nM &2.0 nM).Faldaprevir inhibits viral replication by blocking the breakdown of viral precursor proteins, and is well tolerated with good antiviral activity against hepatitis C virus.

Glecaprevir (ABT-493) is an HCV NS3 4A protease inhibitor, (IC50s: 3.5-11.3 nM).

Telaprevir (Incivek) (VX-950) is an effective inhibitor of HCV NS3-4A serine protease (IC50: 0.35 μM).

Boceprevir (SCH 503034) is a novel, potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with Ki of 14 nM in both enzyme assay and EC90 of 350 nM in cell-based replicon assay.

Simeprevir (TMC435) is a potent HCV NS3 4A protease inhibitor, and inhibits HCV replication with EC50 of 8 nM.

Vedroprevir, also known as GS9451, is a selective hepatitis C virus (HCV) NS3 protease inhibitor in the development of the treatment of genotype 1 (GT1) HCV infection.

Ac-DEMEEC-OH is a competitive inhibitor of the HCV NS3 protease with a Ki of 0.6 µM.

MK-6325 is a potent inhibitor of the HCV NS3 4A protease.

HZ-1157 (DHFR-inhibitor) is a hepatitis C virus (HCV) inhibitor with inhibitory activities toward HCV NS3 4A protease.

Hepatitis C Virus S5A 5B, a synthetic peptide substrate, replicates the NS5A 5B junction of the nonstructural protein (NS), serving as the substrate for examining HCV NS3 protease activity [1].

Ciluprevir is an effective and selective HCV NS3 protease inhibitor with proven antiviral effect in humans. Ciluprevir may be an antiviral agent for individuals infected with non-genotype-1 HCV. In vitro sensitivity studies with Ciluprevir showed a decrea

KK4A peptide, a small peptide derived from the nonstructural protein 4A (NS4A) of Hepatitis C virus (HCV), significantly enhances the catalytic efficiency of the NS3 protease. This peptide serves as a valuable tool for further understanding the function and mechanism of the HCV NS3 protease, thereby advancing research on HCV infections.

Faldaprevir sodium is a potent NS3 NS4A protease inhibitor potentially for the treatment of HCV infection. Faldaprevir is known to inhibit P-glycoprotein, CYP3A4, and UDP-glucuronosyltransferase 1A1.

Paritaprevir (ABT450) is an inhibitor of non-structural protein 3 4A protease with EC50 values of 1 and 0.21 nM for HCV 1a and HCV 1b, respectively.

BI 653048 is a selective, orally active nonsteroidal glucocorticoid agonist (IC50: 55 nM) and an HCV NS3 protease inhibitor.

Variculanol, a compound with antimicrobial, anticancer, and anti-HCV NS3/4A protease properties, is derived from the marine fungus Aspergillus versicolor [1].

Grazoprevir (MK-5172) is a nitrogenous macrocyclic compound used as an inhibitor of the hepatitis C virus NS3 4A protease. Grazoprevir is commonly combined with elbasvir for treating chronic HCV genotype 1 or 4 infections in adults.

BI-1388 is a highly potent inhibitor of HCV NS3 protease activity, inhibiting viral replication for various HCV genotypes and for resistant mutants D168V and R155K.

HCV NS4A Protein (18-40) (JT strain) is a peptide derived from residues 18 to 40 of the HCV NS4A protein, enhancing the catalytic efficiency of NS3 protease [1].

Danoprevir (RG7227) is a peptidomimetic inhibitor of the NS3 4A protease(IC50=0.2-3.5 nM) of hepatitis C virus (HCV).

Paritaprevir free base(ABT-450) is an orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3 NS4A), with potential activity against HCV genotype 1. Upon administration, paritaprevir reversibly binds to the active center and binding site of the HCV NS3 NS4A protease and prevents NS3 NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells. NS3, a serine protease, is essential for the proteolytic cleavage of multiple sites within the HCV polyprotein and plays a key role during HCV ribonucleic acid (RNA) replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, and infection is associated with the development of hepatocellular carcinoma (HCC).